Recent advances in the bcr-abl negative chronic myeloproliferative diseases

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Bennett, Michael ^a   Stroncek, David F ^b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BCR ABL PROTEIN; BIOLOGICAL MARKER; CD59 ANTIGEN; CYANOCOBALAMIN; ERYTHROPOIETIN; JANUS KINASE 2; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; PROTEIN PRV 1; PROTEIN TYROSINE KINASE; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CELL MATURATION; CELL PROLIFERATION; CHROMOSOME MARKER; CHRONIC DISEASE; CLONAL VARIATION; CONFORMATIONAL TRANSITION; ENZYME ACTIVITY; ERYTHROID CELL; FAMILY HISTORY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; JAPAN; LIGAND BINDING; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; PATHOPHYSIOLOGY; PHENOTYPE; POLYCYTHEMIA VERA; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; SIGNAL TRANSDUCTION; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; X CHROMOSOME INACTIVATION;

EID: 33750967896     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-41     Document Type: Review

References (69)

1. Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 1951, 6(4):372-375.
2. Cervantes F: Modern management of myelofibrosis. Br J Haematol 2005, 128(5):583-592.
3. Bench AJ, Cross NC, Huntly BJ, Nacheva EP, Green AR: Myeloproliferative disorders. Best Pract Res Clin Haematol 2001, 14(3):531-551.
4. Kralovics R, Guan Y, Prchal JT: Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002, 30(3):229-236.
5. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L: Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976, 295(17):913-916.
6. Jacobson RJ, Salo A, Fialkow PJ: Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978, 51(2):189-194.
7. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S: Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981, 58(5):916-919.
8. Prchal JF, Axelrad AA: Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 1974, 290(24):1382.
9. Zanjani ED, Lutton JD, Hoffman R, Wasserman LR: Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J Clin Invest 1977, 59(5):841-848.
10. Dai CH, Krantz SB, Dessypris EN, Means RT Jr., Horn ST, Gilbert HS: Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992, 80(4):891-899.
11. Dai CH, Krantz SB, Koury ST, Kollar K: Polycythaemia vera. IV. Specific binding of stem cell factor to normal and polycythaemia vera highly purified erythroid progenitor cells. Br J Haematol 1994, 88(3):497-505.
12. Correa PN, Eskinazi D, Axelrad AA: Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 1994, 83(1):99-112.
13. Axelrad AA, Eskinazi D, Correa PN, Amato D: Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 2000,96(10):3310-3321.
14. Maran J, Prchal J: Polycythemia and oxygen sensing. Pathol Biol (Paris) 2004, 52(5):280-284.
15. Michiels JJ, Raeve HD, Berneman Z, Bockstaele DV, Hebeda K, Lam K, Schroyens W: The 2001 world health organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 2006, 32(4):307-340.
16. Rolovic Z, Basara N, Gotic M, Sefer D, Bogdanovic A: The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis. Br J Haematol 1995, 90(2):326-331.
17. Escoffre-Barbe M, Amiot L, Beaucournu P, Jego P, Grulois I, Grosbois B, Bernard M, Fest T, Lamy T, Fardel O: Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera. Am J Hematol 2006, 81(7):554-556.
18. Taksin AL, Couedic JP, Dusanter-Fourt I, Masse A, Giraudier S, Katz A, Wendling F, Vainchenker W, Casadevall N, Debili N: Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 1999, 93(1):125-139.
19. Temerinac S, Klippel S, Strunck E, Roder S, Lubbert M, Lange W, Azemar M, Meinhardt G, Schaefer HE, Pahl HL: Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 2000, 95(8):2569-2576.
20. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, Skoda RC: Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003, 102(5):1869-1871.
21. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT: Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003, 101(8):3294-3301.
22. Ricksten A, Palmqvist L, Wasslavik C, Johansson P, Andreasson B, Safai-Kutti S, Kutti J: High PRV-I mRNA expression, a diagnostic marker for polycythemia, vera [abstract]. Blood 2002, 100:3156a.
23. Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, Leichtle R, Green AR, Griesshammer M, Heimpel H, Pahl HL: Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003, 102(10):3569-3574.
24. Bench AJ, Pahl HL: Chromosomal abnormalities and molecular markers in myeloproliferative disorders. Semin Hematol 2005, 42(4):196-205.
25. Cilloni D, Carturan S, Gottardi E, Messa F, Fava M, Defilippi I, Arruga F, Saglio G: Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients. Blood 2004, 103(6):2428; author reply 2429.
26. Caruccio L, Bettinotti M, Director-Myska AE, Arthur DC, Stroncek D: The gene overexpressed in polycythemia rubra vera, PRV-1, and the gene encoding a neutrophil alloantigen, NBI, are alleles of a single gene, CD177, in chromosome band 19q13.31. Transfusion 2006, 46(3):441-447.
27. Stroncek DF, Caruccio L, Bettinotti M: CD177: A member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera. J Transl Med 2004, 2(1):8.
28. Gohring K, Wolff J, Doppi W, Schmidt KL, Fenchel K. Pralle H, Sibelius U, Bux J: Neutrophil CD177 (NBI gp, HNA-2a) expression is increased in severe bacterial infections and polycythaemia vera. Br J Haematol 2004, 126(2):252-254.
29. Klippel S, Strunck E, Busse CE, Behringer D, Pahl HL: Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. Blood 2002, 100(7):2441-2448.
30. Ronne E, Pappot H, Grondahl-Hansen J, Hoyer-Hansen G, Plesner T, Hansen NE, Dano K: The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995, 89(3):576-581.
31. Ihle JN: Cytokine receptor signalling. Nature 1995, 377(6550):591-594.
32. Berchtold S, Morid R, Gouilleux F, Silvennoinen O, Beisenherz C, Pfitzner E, Wissler M, Stocklin E, Groner B: Cytokine receptor-independent, constitutively active variants of STATS. J Biol Chem 1997, 272(48):30237-30243.
33. Saharinen P, Vihinen M, Silvennoinen O: Autoinhibition of jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003, 14(4):1448-1459.
34. Lindauer K, Loerting T, Liedl KR, Kroemer RT: Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001, 14(1):27-37.
35. Luo, H, Rose P, Barber D, Hanratty WP, Lee S, Roberts TM, D'Andrea AD, Dearolf CR: Mutation in the Jak kinase JH2 domain hyper-activates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol 1997, 17(3):1562-1571.
36. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037):1144-1148.
37. Baxter EJ, Scott LM, Campbell FJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464):1054-1061.
38. Levine RL, Wadleigh M, Cools J, Ebert BL, YVernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TP, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4):387-397.
39. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine 2005, 352(17):1779-1790.
40. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ: Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280(24):22788-22792.
41. Cazzola M, Passamonti F: Not just clonall expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. Haematologicathe Hematology Journal 2006, 91(2):159-161.
42. Scott LM, Scott MA, Campbell PJ, Green AR: Progenitors homozygous for the V617F JAK2 mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006.
43. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP: Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006.
44. Kralovics R, Skoda RC: Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 2005, 19(1):1-13.
45. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A: JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005, 131(2):208-213.
46. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366(9501):1945-1953.
47. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi AM: Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005, 19(10):1847-1849.
48. Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N, Conejero C, Briere J, Fenaux P, Chomienne C, Grandchamp B: Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 2006, 20(6):1181-1183.
49. Sidon P, El Housni H, Dessars B, Heimann P: The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006.
50. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995, 86(8):3118-3122.
51. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998, 92(9):3362-3367.
52. Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, Clark RE: Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 2005, 90(10):1315-1323.
53. Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP: Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl Med 1995, 333(8):487-493.
54. Hunter MG, Jacob A, O'Donnell L C, Agler A, Druhan LJ, Coggeshall KM, Avalos BR: Loss of SHIP and CIS recruitment to the granulocyte colony-stimulating factor receptor contribute to hyperproliferative responses in severe congenital neutropenia/acute myelogenous leukemia. J Immunol 2004, 173(8):5036-5045.
55. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F: A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990, 63(6):1137-1147.
56. Wendling F, Varlet P, Charon M, Tambourin P: MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology 1986, 149(2):242-246.
57. Sabath DF, Kaushansky K, Broudy VC: Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 1999, 94(1):365-367.
58. Horikawa Y, Matsumura I, Hashimoto K, Shiraga M, Kosugi S, Tadokoro S, Kato T, Miyazaki H, Tomiyama Y, Kurata Y, Matsuzawa Y, Kanakura Y: Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997, 90(10):4031-4038.
59. Moliterno AR, Hankins WD, Spivak JL: Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998, 338(9):572-580.
60. Moliterno AR, Spivak JL: Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood 1999, 94(8):2555-2561.
61. Westwood NB, Raj K, Messsinezy M, Pearson TC: Platelet expression of Mpl is diminshed in reactive thrombocytosis and in myeloproliferative disorders but is normal in secondary erythrocytosis. Blood 1999, 94(suppl. 1):491.
62. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC: An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998, 18(1):49-52.
63. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, Tsuboi K, Nitta M, Miyazaki H, Iida S, Ueda R: Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004, 103(11):4198-4200.
64. Moliterno, AR, Williams DM, Gutierrez-Alamillo, U, Salvatori k Ingersoll RG, Spivak JL: Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A 2004, 101(31):11444-11447.
65. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN: An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood 2006, 107(5):1864-1871.
66. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, Deangelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL: MPLW515L is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med 2006, 3(7):e270.
67. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa PA Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006.
68. Thiele J, Kvasnicka HM: Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost 2006, 32(3):219-230.
69. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106(4):1207-1209.